ABSTRACT
A novel nucleoside analog BMS-181165 with potent activity against varicella-zoster virus was tested for efficacy in a simian varicella virus infection in African green monkeys. BMS-181165 was effective in preventing the development of a rash, decreasing the development of viremia and preventing death in infected monkeys when administered orally at 4, 16 or 64 mg/kg/day. The compound is well orally absorbed in monkeys, between 44 to 50% oral bioavailability, and may prove of value in therapy of varicella-zoster infections in humans.
Subject(s)
Antiviral Agents/pharmacokinetics , Herpesviridae Infections/prevention & control , Herpesvirus 1, Cercopithecine , Uridine/analogs & derivatives , Administration, Oral , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/blood , Biological Availability , Chlorocebus aethiops , Disease Models, Animal , Herpesviridae Infections/complications , Treatment Outcome , Uridine/administration & dosage , Uridine/blood , Uridine/pharmacokinetics , Viremia/prevention & controlABSTRACT
Stable, broadly tunable cw lasing has been obtained from color centers in additively colored NaCl doped with K. The laser tunes from 1.42 to 1.76 microm with a peak output power of 530 mW when pumped by 6 W from a 1.06-microm Nd:YAG laser. Output power is strongly enhanced by exposing the crystal to an auxiliary UV light during lasing. No fading of output power has been observed over extended periods. The laser operates at 77 K; however, the crystals can be stored at room temperature. The active color center is tentatively identified as an (F(2)(+))(A) center.
